LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Abstract Background Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549::BRAF fusions and BRAF V600E mutations. This makes pLGG an ideal can...

Full description

Bibliographic Details
Main Authors: Cornelis M. van Tilburg, Lindsay B. Kilburn, Sébastien Perreault, Rene Schmidt, Amedeo A. Azizi, Ofelia Cruz-Martínez, Michal Zápotocký, Katrin Scheinemann, Antoinette Y. N. Schouten-van Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driever, Shivaram Avula, David S. Ziegler, David Capper, Arend Koch, Felix Sahm, Jiaheng Qiu, Li-Pen Tsao, Samuel C. Blackman, Peter Manley, Till Milde, Ruth Witt, David T. W. Jones, Darren Hargrave, Olaf Witt
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Chemotherapy
First-line
Pediatric low-grade glioma
pLGG
Tovorafenib
Child
Online Access:https://doi.org/10.1186/s12885-024-11820-x

Internet

https://doi.org/10.1186/s12885-024-11820-x

Similar Items